Home > > > > > Report Detail

Pain Drug Development Pipeline Review, 2018

Publisher Name :
Date: 24-Sep-2018
No. of pages: 148

This report provides an overview of the pipeline landscape for pain disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-operative pain, fibromyalgia, complex regional pain syndrome (CRPS) and visceral pain, and features dormant and discontinued products.

Pain is one of the main post-operative adverse outcomes causing distress to patients. Causes of post-operative pain include peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics. There are 74 products in development for this indication.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs. There are 21 products in development for this indication.

CRPS is a chronic pain condition that most often affects one limb, usually after an injury. CRPS is divided into two types: CRPS-I (individuals without a confirmed nerve injury) and CRPS-II (when there is an associated, confirmed nerve injury). Symptoms include stiffness in the affected joints, changes in nail and hair growth patterns, dystonia and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids and local anesthetic creams. There are seven products in development for this indication.

Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or nonsteroidal anti-inflammatory drugs and pain modifiers such as tricyclic antidepressants or anticonvulsants. There are 38 products in development for this indication.

Molecular targets acted on by products in development for pain disorders include beta nerve growth factor, cannabinoid receptors, opioid receptors and protein kinases. Companies operating in this pipeline space include NeurAxon, Abide Therapeutics and Pfizer.

Scope


  • Which companies are the most active within each pipeline?

  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

  • What are the most important R&D milestones and data publications to have happened in this disease area?


Reasons to buy


  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Pain Drug Development Pipeline Review, 2018

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8

2 Introduction 9
2.1 Pain Report Coverage 9
2.2 Post-Operative Pain - Overview 9
2.3 Fibromyalgia - Overview 9
2.4 Complex Regional Pain Syndrome - Overview 9
2.5 Visceral Pain - Overview 9

3 Therapeutics Development 10
3.1 Post-Operative Pain 10
3.2 Fibromyalgia 18
3.3 Complex Regional Pain Syndrome 22
3.4 Visceral Pain 25

4 Therapeutics Assessment 32
4.1 Post-Operative Pain 32
4.2 Fibromyalgia 42
4.3 Complex Regional Pain Syndrome 49
4.4 Visceral Pain 54

5 Companies Involved in Therapeutics Development 62
5.1 Post-Operative Pain 62
5.2 Fibromyalgia 85
5.3 Complex Regional Pain Syndrome 91
5.4 Visceral Pain 93

6 Dormant Projects 103
6.1 Post-Operative Pain 103
6.2 Fibromyalgia 106
6.3 Complex Regional Pain Syndrome 107
6.4 Visceral Pain 108

7 Discontinued Products 111
7.1 Post-Operative Pain 111
7.2 Fibromyalgia 112
7.3 Visceral Pain 112

8 Product Development Milestones 114
8.1 Post-Operative Pain 114
8.2 Fibromyalgia 127
8.3 Complex Regional Pain Syndrome 138
8.4 Visceral Pain 141

9 Appendix 147
9.1 Methodology 147
9.2 Coverage 147
9.3 Secondary Research 147
9.4 Primary Research 147
9.5 Expert Panel Validation 147
9.6 Contact Us 148
9.7 Disclaimer 148

List of Tables

Table 1: Number of Products under Development for Post-Operative Pain 10
Table 2: Number of Products under Development by Companies, Post-Operative Pain 12
Table 3: Number of Products under Development by Universities/Institutes, Post-Operative Pain 14
Table 4: Products under Development by Companies, Post-Operative Pain 15
Table 5: Products under Development by Universities/Institutes, Post-Operative Pain 18
Table 6: Number of Products under Development for Fibromyalgia 19
Table 7: Number of Products under Development by Companies, Fibromyalgia 20
Table 8: Number of Products under Development by Universities/Institutes, Fibromyalgia 20
Table 9: Products under Development by Companies, Fibromyalgia 21
Table 10: Products under Development by Universities/Institutes, Fibromyalgia 22
Table 11: Number of Products under Development for Complex Regional Pain Syndrome 22
Table 12: Number of Products under Development by Companies, Complex Regional Pain Syndrome 23
Table 13: Number of Products under Development by Universities/Institutes, Complex Regional Pain Syndrome 24
Table 14: Products under Development by Companies, Complex Regional Pain Syndrome 24
Table 15: Products under Development by Universities/Institutes, Complex Regional Pain Syndrome 24
Table 16: Number of Products under Development for Visceral Pain 25
Table 17: Number of Products under Development by Companies, Visceral Pain 27
Table 18: Number of Products under Development by Universities/Institutes, Visceral Pain 28
Table 19: Products under Development by Companies, Visceral Pain 29
Table 20: Products under Development by Universities/Institutes, Visceral Pain 31
Table 21: Number of Products by Stage and Target, Post-Operative Pain 33
Table 22: Number of Products by Stage and Mechanism of Action, Post-Operative Pain 36
Table 23: Number of Products by Stage and Route of Administration, Post-Operative Pain 39
Table 24: Number of Products by Stage and Molecule Type, Post-Operative Pain 41
Table 25: Number of Products by Stage and Target, Fibromyalgia 43
Table 26: Number of Products by Stage and Mechanism of Action, Fibromyalgia 45
Table 27: Number of Products by Stage and Route of Administration, Fibromyalgia 47
Table 28: Number of Products by Stage and Molecule Type, Fibromyalgia 48
Table 29: Number of Products by Stage and Target, Complex Regional Pain Syndrome 50
Table 30: Number of Products by Stage and Mechanism of Action, Complex Regional Pain Syndrome 51
Table 31: Number of Products by Stage and Route of Administration, Complex Regional Pain Syndrome 53
Table 32: Number of Products by Stage and Molecule Type, Complex Regional Pain Syndrome 53
Table 33: Number of Products by Stage and Target, Visceral Pain 55
Table 34: Number of Products by Stage and Mechanism of Action, Visceral Pain 57
Table 35: Number of Products by Stage and Route of Administration, Visceral Pain 59
Table 36: Number of Products by Stage and Molecule Type, Visceral Pain 61
Table 37: Post-Operative Pain - Pipeline by Abide Therapeutics Inc 62
Table 38: Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc 62
Table 39: Post-Operative Pain - Pipeline by Adynxx Inc 63
Table 40: Post-Operative Pain - Pipeline by AngioChem Inc 63
Table 41: Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company Inc 64
Table 42: Post-Operative Pain - Pipeline by Apsen Farmaceutica SA 64
Table 43: Post-Operative Pain - Pipeline by Cadila Healthcare Ltd 65
Table 44: Post-Operative Pain - Pipeline by Camurus AB 65
Table 45: Post-Operative Pain - Pipeline by Cara Therapeutics Inc 66
Table 46: Post-Operative Pain - Pipeline by Center Laboratories Inc 66
Table 47: Post-Operative Pain - Pipeline by CerSci Therapeutics Inc 67
Table 48: Post-Operative Pain - Pipeline by Colby Pharmaceutical Co 67
Table 49: Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA 68
Table 50: Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc 68
Table 51: Post-Operative Pain - Pipeline by EyeGate Pharmaceuticals Inc 69
Table 52: Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp 69
Table 53: Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc 70
Table 54: Post-Operative Pain - Pipeline by Heron Therapeutics Inc 70
Table 55: Post-Operative Pain - Pipeline by Immupharma Plc 71
Table 56: Post-Operative Pain - Pipeline by Innocoll AG 71
Table 57: Post-Operative Pain - Pipeline by Insys Therapeutics Inc 72
Table 58: Post-Operative Pain - Pipeline by Ionis Pharmaceuticals Inc 72
Table 59: Post-Operative Pain - Pipeline by iX Biopharma Ltd 73
Table 60: Post-Operative Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd 73
Table 61: Post-Operative Pain - Pipeline by Lipocure Ltd 74
Table 62: Post-Operative Pain - Pipeline by Liquidia Technologies Inc 74
Table 63: Post-Operative Pain - Pipeline by Lumosa Therapeutics Co Ltd 74
Table 64: Post-Operative Pain - Pipeline by Medtronic Plc 75

List of Figures

Figure 1: Number of Products under Development for Post-Operative Pain 10
Figure 2: Number of Products under Development by Companies, Post-Operative Pain 11
Figure 3: Number of Products under Development by Universities/Institutes, Post-Operative Pain 14
Figure 4: Number of Products under Development for Fibromyalgia 18
Figure 5: Number of Products under Development by Companies, Fibromyalgia 19
Figure 6: Number of Products under Development for Complex Regional Pain Syndrome 22
Figure 7: Number of Products under Development by Companies, Complex Regional Pain Syndrome 23
Figure 8: Number of Products under Development for Visceral Pain 25
Figure 9: Number of Products under Development by Companies, Visceral Pain 26
Figure 10: Number of Products under Development by Universities/Institutes, Visceral Pain 28
Figure 11: Number of Products by Top 10 Targets, Post-Operative Pain 32
Figure 12: Number of Products by Stage and Top 10 Targets, Post-Operative Pain 32
Figure 13: Number of Products by Top 10 Mechanism of Actions, Post-Operative Pain 35
Figure 14: Number of Products by Stage and Top 10 Mechanism of Actions, Post-Operative Pain 35
Figure 15: Number of Products by Top 10 Routes of Administration, Post-Operative Pain 38
Figure 16: Number of Products by Stage and Top 10 Routes of Administration, Post-Operative Pain 38
Figure 17: Number of Products by Molecule Types, Post-Operative Pain 40
Figure 18: Number of Products by Stage and Molecule Types, Post-Operative Pain 40
Figure 19: Number of Products by Top 10 Targets, Fibromyalgia 42
Figure 20: Number of Products by Stage and Top 10 Targets, Fibromyalgia 42
Figure 21: Number of Products by Top 10 Mechanism of Actions, Fibromyalgia 44
Figure 22: Number of Products by Stage and Top 10 Mechanism of Actions, Fibromyalgia 44
Figure 23: Number of Products by Routes of Administration, Fibromyalgia 46
Figure 24: Number of Products by Stage and Routes of Administration, Fibromyalgia 46
Figure 25: Number of Products by Molecule Types, Fibromyalgia 47
Figure 26: Number of Products by Stage and Molecule Types, Fibromyalgia 48
Figure 27: Number of Products by Targets, Complex Regional Pain Syndrome 49
Figure 28: Number of Products by Stage and Targets, Complex Regional Pain Syndrome 49
Figure 29: Number of Products by Mechanism of Actions, Complex Regional Pain Syndrome 50
Figure 30: Number of Products by Stage and Mechanism of Actions, Complex Regional Pain Syndrome 51
Figure 31: Number of Products by Routes of Administration, Complex Regional Pain Syndrome 52
Figure 32: Number of Products by Stage and Top 10 Routes of Administration, Complex Regional Pain Syndrome 52
Figure 33: Number of Products by Stage and Molecule Types, Complex Regional Pain Syndrome 53
Figure 34: Number of Products by Top 10 Targets, Visceral Pain 54
Figure 35: Number of Products by Stage and Top 10 Targets, Visceral Pain 54
Figure 36: Number of Products by Top 10 Mechanism of Actions, Visceral Pain 56
Figure 37: Number of Products by Stage and Top 10 Mechanism of Actions, Visceral Pain 56
Figure 38: Number of Products by Routes of Administration, Visceral Pain 58
Figure 39: Number of Products by Stage and Routes of Administration, Visceral Pain 59
Figure 40: Number of Products by Molecule Types, Visceral Pain 60
Figure 41: Number of Products by Stage and Molecule Types, Visceral Pain 60

  • Central Nervous System Disorder Drugs Industry Forecasts - China Focus
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 116
    This study focuses on China's Central Nervous System Disorder Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of g......
  • Central Nervous System Disorder Drugs Companies in China
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 48
    This study focuses on China's Central Nervous System Disorder Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market fo......
  • Central Nervous System Disorder Drugs Markets in China
    Published: 27-Nov-2023        Price: US 4000 Onwards        Pages: 214
    China's demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, in......
  • Global Drugs of Nervous System Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 14-Nov-2023        Price: US 3380 Onwards        Pages: 108
    Market Overview of Global Drugs of Nervous System market: According to our latest research, the global Drugs of Nervous System market looks promising in the next 5 years. As of 2022, the global Drugs of Nervous System market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, ......
  • Central Nervous System Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 650
    Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of central nervous system deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal te......
  • Global Drugs of Nervous System Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 24-Feb-2023        Price: US 3260 Onwards        Pages: 123
    Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson's disease, Alzheimer's disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson's disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. The Drugs of Nervous System market revenue was XX Million USD in 2022, and will r......
  • Global Drugs of Nervous System Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 26-Jan-2023        Price: US 3450 Onwards        Pages: 111
    Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson's disease, Alzheimer's disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson's disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. The report focuses on the Drugs of Nervous System market size, segment si......
  • Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 30-Nov-2022        Price: US 2000 Onwards        Pages: 71
    Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Drugs In Development, 2022, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape. Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures......
  • Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 30-Nov-2022        Price: US 2000 Onwards        Pages: 40
    Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Drugs In Development, 2022, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape. Metachromatic leukodystrophy is an inherited disorder characterized ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs